1+
INNs
1+
Products in pipeline
1+
New dossiers annually
1+
Registered MAs
Our production capability is supported by extensive expertise in the pharmaceutical industry, enabling us to provide high-quality and affordable healthcare solutions to patients across 14 therapeutic areas.
Farmak’s range of medicines is continuously expanding with the addition of 20 INNs currently in development and registration.
View Product CatalogueFarmak AG acquires Polish pharmaceutical company Symphar Sp. z o.o.
As of 27 March 2024, Farmak AG has successfully finalized its acquisition of Symphar Sp. z o.o., becoming the sole owner of the Polish pharmaceutical company through a cash transaction.
The acquisition represents a part of Farmak’s international expansion strategy marking its latest M&A after the last year’s acquisitions in the Czech Republic and Slovakia. It expands Farmak’s market share and strengthens its position in diabetology, psychiatry, neurology, women health and other segments in the EU. Management anticipates accelerated sales and profitability growth thanks to be the synergies with the existing Polish operations acquired in 2016. An ambitious investment plan is in place to facilitate the further development of the company and further strengthening of relations with existing suppliers and other partners.
The transaction is a result of a thorough preparation and evaluation of different options in the Polish market. Symphar’s business and operations fully comply with the legal requirements and high ethical and corporate standards of Farmak. The closing took place after fulfilling the deal conditions and the relevant regulatory requirements.
Today starts a new chapter for Farmak and Symphar. We're looking forward to working with our new team members to grow our combined business and keep providing reliable treatments to patients and caregivers in Poland
Viktor Kostiuk
CEO at FARMAK AG
About Farmak
Farmak, an international pharmaceutical company established in 1925, operates with a focus on research and development, manufacturing, and global sales and marketing of generics. With manufacturing and R&D facilities in Ukraine and Spain, Farmak has reached a strong presence globally.
The company owns 10 commercial offices strategically positioned around the world, including Ukraine, Poland, the Czech Republic, Slovakia, Central Asia, the Asia Pacific region, the Middle East, and Western Europe. This extensive network underscores Farmak’s commitment to drive quality medicines worldwide.
About Symphar
Symphar is a Polish pharmaceutical company with its offices in Warsaw. Its team of 90 professionals works with more than 50 products in the diabetology, gynecology, psychiatry, neurology and other therapeutic areas. In 2023, Symphar reached over EUR 22m revenue following its long-lasting period of stable and profitable growth.
Advisers
FinPoint investment banking firm has acted as an exclusive financial adviser to Farmak on the acquisition. Swiss Merchant Corporation SA, a Swiss group specialized in private equity investments and M&A transactions, has acted as an exclusive financial adviser to the seller.
Broad range of theraupetic areas
Farmak portfolio is tailored to meet the specific healthcare needs of local markets. Products are aligned with local market demand, ensuring they meet the specific requirements of the region.
Global presence
We continually expand our market presence in well-regulated and emerging markets by developing and producing high-quality products and maintaining a robust business reputation.
Quality: the heartbeat of our processes
At Farmak, quality is our cornerstone. With adherence to international standards, continuous improvement, and strict quality control, we ensure the utmost safety and efficacy of our pharmaceuticals. Your confidence is our priority, making Farmak your trusted partner in specialty generics.
| 1 | Dedicated Scientists Driving Innovation |
| 1 | Development Centers with 13 Advanced Laboratories in 2 Countries |
| 1 | Successful Inspections by International Regulatory Authorities and Partnerships over last 5 years |
| 1 | Approved Testing Methods by Leading Pharmacopoeias |
| 1 | Modern Quality Control Laboratories |
Reliable business partner
Partnering with Farmak means gaining a trusted and reliable business partner committed to providing high-quality pharmaceutical products promptly and precisely where they are needed
-
Competitive pricing
We offer reasonable pricing for our products without compromising quality
-
Client-oriented approach
We understand the unique needs of our partners and work closely with them to find tailored solutions
-
Short lead times
Quickly respond to our partners' needs with short lead times for standard and custom orders
-
Flexibility and agility
Adapt to changes in market demand and provide flexible solutions to meet our partners' evolving needs
Partnering with Farmak means gaining a trusted and reliable business partner committed to providing high-quality pharmaceutical products promptly and precisely where they are needed